《Medicalxpress,12月7日,Biomarker discovery makes early detection of high-risk COVID-19 patients possible》

  • 来源专题:COVID-19科研动态监测
  • 编译者: YUTING
  • 发布时间:2021-12-15
  • Researchers have discovered a biomarker that could assist in the early identification of people at high risk of developing severe COVID-19.

    Led by computational researchers from WEHI, in collaboration with The University of Queensland, Queensland University of Technology and Hospital Marcelino Champagnat in Brazil, the study used advanced spatial transcriptomic techniques to screen for genes associated with excessive inflammation in the lungs, a key indicator of severe COVID-19.

    Recently published in the European Respiratory Journal the findings have the potential to revolutionize the way patients are treated and alleviate pressure on the nation's healthcare system.

    The researchers are now participating in an international effort to translate this research into a diagnostic test to identify patients at high-risk of severe COVID-19 during the early stages of their infection, to better target health-care intervention and prevent ICU admissions associated with severe disease.

  • 原文来源:https://medicalxpress.com/news/2021-12-biomarker-discovery-early-high-risk-covid-.html
相关报告
  • 《Medicalxpress,1月13日,WHO recommends two new drugs to treat patients with COVID-19》

    • 来源专题:COVID-19科研动态监测
    • 编译者:YUTING
    • 发布时间:2022-01-26
    • The drug baricitinib (a type of drug known as a Janus kinase (JAK) inhibitor, also used to treat rheumatoid arthritis) is strongly recommended for patients with severe or critical COVID-19 in combination with corticosteroids, says a WHO Guideline Development Group of international experts in The BMJ today. Their strong recommendation is based on moderate certainty evidence that it improves survival and reduces the need for ventilation, with no observed increase in adverse effects. The WHO experts note that baricitinib has similar effects to other arthritis drugs called interleukin-6 (IL-6) inhibitors so, when both are available, they suggest choosing one based on cost, availability, and clinician experience. It is not recommended to use both drugs at the same time. However, the experts advise against the use of two other JAK inhibitors (ruxolitinib and tofacitinib) for patients with severe or critical COVID-19 because low certainty evidence from small trials failed to show benefit and suggests a possible increase in serious side effects with tofacitinib. In the same guideline update, WHO also makes a conditional recommendation for the use of the monoclonal antibody sotrovimab in patients with non-severe COVID-19, but only in those at highest risk of hospitalization, reflecting trivial benefits in those at lower risk. A similar recommendation has been made by WHO for another monoclonal antibody drug (casirivimab-imdevimab). The experts also note that there were insufficient data to recommend one monoclonal antibody treatment over another—and they acknowledge that their effectiveness against new variants like omicron is still uncertain. As such, they say guidelines for monoclonal antibodies will be updated when additional data become available.
  • 《Nature,12月7日,Development of a novel risk score to predict mortality in patients admitted to hospital with COVID-19》

    • 来源专题:COVID-19科研动态监测
    • 编译者:zhangmin
    • 发布时间:2020-12-22
    • Development of a novel risk score to predict mortality in patients admitted to hospital with COVID-19 Ying X. Gue, Maria Tennyson, Jovia Gao, Shuhui Ren, Rahim Kanji & Diana A. Gorog Scientific Reports volume 10, Article number: 21379 (2020) Abstract Patients hospitalised with COVID-19 have a high mortality. Identification of patients at increased risk of adverse outcome would be important, to allow closer observation and earlier medical intervention for those at risk, and to objectively guide prognosis for friends and family of affected individuals. We conducted a single-centre retrospective cohort study in all-comers with COVID-19 admitted to a large general hospital in the United Kingdom. Clinical characteristics and features on admission, including observations, haematological and biochemical characteristics, were used to develop a score to predict 30-day mortality, using multivariable logistic regression. We identified 316 patients, of whom 46% died within 30-days. We developed a mortality score incorporating age, sex, platelet count, international normalised ratio, and observations on admission including the Glasgow Coma Scale, respiratory rate and blood pressure.